Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus

Table 3 Comparison of renal function before and after treatment with DPP-4 inhibitors

Index	Groups	Before treatment	After treatment	The change (ΔA)	P
CRE	All patients	73.80 ± 20.23	74.83 ± 20.67	1.31	0.106
eGFR	All patients	82.38 ± 5.51	81.46 ± 15.50	0.92	0.062
BUN	All patients	6.37 ± 5.97	7.94 ± 21.66	1.57	0.246
CRE	Medication time ≤ 12	62.75 ± 15.60	62.68 ± 16.45	− 0.07	0.952
CRE	Medication time > 12	77.44 ± 20.12	78.69 ± 20.35	+ 1.25	0.105
eGFR	Medication time ≤ 12	86.31 ± 12.90	86.13 ± 13.03	− 0.19	0.845
eGFR	Medication time > 12	81.01 ± 16.02	79.98 ± 15.93	− 1.03	0.078
BUN	Medication time ≤ 12	5.57 ± 1.88	11.92 ± 45.75	6.35	0.299
BUN	Medication time > 12	6.62 ± 6.72	6.94 ± 6.80	+ 0.32	0.628
CRE	eGFR ≥ 90 mL/min/1.73 m²	82.72 ± 18.85	82.58 ± 20.24	− 0.14	0.875
CRE	eGFR < 90 mL/min/1.73 m²	58.42 ± 10.78	61.56 ± 12.81	+ 3.15	< 0.001
eGFR	eGFR ≥ 90 mL/min/1.73 m²	74.27 ± 13.27	74.10 ± 14.02	− 0.17	0.815
eGFR	eGFR < 90 mL/min/1.73 m²	96.92 ± 5.12	94.64 ± 6.95	− 2.28	< 0.001
BUN	eGFR ≥ 90 mL/min/1.73 m²	6.96 ± 7.41	9.32 ± 27.17	+ 2.36	0.273
BUN	eGFR < 90 mL/min/1.73 m²	5.37 ± 1.24	5.62 ± 1.30	+ 0.24	0.079

ISSN: 1758-5996